Seeking Alpha

Albany Molecular falls after Bristol-Myers terminates development of TRD drug

  • Albany Molecular Research (AMRI -13.2%) plunges after an SEC filing shows Bristol-Myers (BMY -1.4%) has terminated the development of the triple reuptake inhibitor BMS-820836.
  • According to BMY, the investigational drug failed to show superiority over duloxetine or escitalopram in a Phase II study for Treatment Resistant Depression.
  • AMRI says the news will have "no impact on [its] financial guidance or forecasts." (8-K)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector